Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.

An amendment to this paper has been published and can be accessed via the original article.

Correction to: Arthritis Research & Therapy (2020) 22:47

https://doi.org/10.1186/s13075-020-2125-2

Following publication of the original article [1], the authors identified an error in the 95% CI bars plotted on the graphs of Fig. 6a, b, and c. The CI numbers in the table below the graph are correct, but the upper and lower limit bars plotted on the graph are incorrect. The corrected Fig. 6 is given below.

Fig. 6

Adverse events of special interest per 100 patient-years during the overall period: a serious infections, b herpes zoster-related disease, c malignancies (SAF). Patient-years was calculated from initial dose up to first incidence of the event for patients who had at least one event, and from initial dose through follow up for patients who had no events; IR was calculated as (100 × number of patients with ≥ 1 incidence/total patient-years) CI confidence interval, IR incidence rate